New research conducted by scientists at the Max Planck Institute suggests that glial cells play a key role in producing amyloid beta, a protein associated with Alzheimer’s disease. This study challenges the conventional belief that neurons were the sole source of this protein and could potentially lead to new treatment approaches for the disease. Alzheimer’s disease, which is the most common form of dementia, impacts millions of people worldwide, and cases are reportedly increasing. Beta-amyloid, a naturally occurring brain protein, is crucial to the progression of the disease as it forms plaques between neurons, leading to damage.
The new research, published in Nature Neuroscience, reveals that not only neurons but also certain glial cells in the brain produce amyloid beta. The team disabled the enzyme BACE1 in neurons and oligodendrocytes in mice to study plaque formation using 3D light-sheet microscopy. The results showed that plaques formed when a specific level of amyloid beta from neurons was present, with oligodendrocytes contributing to plaque build-up. Removing the BACE1 gene in neurons led to a significant decrease in plaques. If BACE1 inhibition is successful before reaching this threshold, plaque formation might be delayed, potentially slowing the early progression of Alzheimer’s disease.
Andrew Octavian Sasmita, PhD, emphasized that silencing oligodendroglial BACE and beta-amyloid production could be an alternative target for reducing beta-amyloid levels in the brain. He hopes that these findings will aid in the development of anti-beta-amyloid therapies focused on early disease stages before the threshold for plaque deposition is reached. The study’s findings challenge the neuron-centric view of beta-amyloid production and underscore the importance of reevaluating the basic biology of APP and beta-amyloid.
Bryen Jordan, PhD, a professor of neuroscience, highlighted the significance of the study in redirecting Alzheimer’s research funding toward investigating glial cells. The study’s findings have potentially far-reaching implications for the understanding of oligodendrocytes’ role in brain functions and neurodegenerative diseases like Alzheimer’s. By identifying oligodendrocytes as substantial contributors to beta-amyloid production, new avenues for therapeutic development targeting these glial cells alongside neurons could be explored. The study’s findings may also suggest that white matter abnormalities observed in Alzheimer’s patients could play a more significant role in the disease’s development than previously thought.
Overall, the research conducted by the Max Planck Institute sheds new light on the role of glial cells in Alzheimer’s disease and challenges traditional views on beta-amyloid production. By expanding the focus of Alzheimer’s research to include glial cells, novel therapeutic approaches targeting both neurons and glial cells may be developed. This study has the potential to reshape the understanding of the disease and lead to more effective treatment strategies aimed at delaying plaque formation and slowing the progression of Alzheimer’s at an early stage.
